OncoMatch/Clinical Trials/NCT06069726
A Multicenter Trial to Identify Optimal Atezolizumab Biomarkers in the Setting of Recurrent Glioblastoma. The MOAB Trial
Is NCT06069726 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Atezolizumab for recurrent glioblastoma.
Treatment: Atezolizumab — This is to study if neoadjuvant atezolizumab therapy is beneficial for patients with recurrent glioblastoma and a low mutational burden.
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Biomarker criteria
Required: IDH1 wild-type
Prior therapy
Must have received: radiation therapy
Clinical or radiologic evidence of first or second recurrence following radiation and TMZ
Must have received: temozolomide (temozolomide)
Clinical or radiologic evidence of first or second recurrence following radiation and TMZ
Cannot have received: immunotherapy
Prior treatment with immunotherapy
Cannot have received: bevacizumab (bevacizumab)
Exception: permitted if necessary to control inflammatory side effects 5-7mg/kg Q 3/52 for up to 3 cycles
Prior treatment with bevacizumab within 4 weeks before biopsy
Cannot have received: CD137 agonist
Prior treatment with CD137 agonists
Cannot have received: immune checkpoint blockade therapy
Prior treatment with immune checkpoint blockade therapies, including anti-CTLA-4, anti-PD-1, and anti-PD-L1 therapeutic antibodies
Cannot have received: investigational therapy
Treatment with investigational therapy within 28 days prior to initiation of study treatment
Cannot have received: allogeneic stem cell or solid organ transplantation
Prior allogeneic stem cell or solid organ transplantation
Lab requirements
Blood counts
Hemoglobin ≥ 9 g/dl; Platelet count ≥ 75,000/µl; Neutrophil count ≥ 1000 cells/mm3; Prothrombin and Partial Thromboplastin Times ≤ 1.2 x ULN
Kidney function
Creatinine ≤ 1.5 x ULN (Cockcroft-Gault formula)
Liver function
Total bilirubin ≤ 1.5 x ULN (≤ 3.0 x ULN if Gilbert's Syndrome); ALP ≤ 2.5 x ULN; AST and ALT ≤ 2.5 x ULN; Serum albumin ≥ 25 g/L (2.5 g/dL)
Adequate organ function: Hemoglobin ≥ 9 g/dl; Platelet count ≥ 75,000/µl; Neutrophil count ≥ 1000 cells/mm3; Creatinine ≤ 1.5 x ULN; Total bilirubin ≤ 1.5 x ULN (≤ 3.0 x ULN if Gilbert's Syndrome); ALP ≤ 2.5 x ULN; AST and ALT ≤ 2.5 x ULN; Serum albumin ≥ 25 g/L (2.5 g/dL); Prothrombin and Partial Thromboplastin Times ≤ 1.2 x ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of California, San Francisco · San Francisco, California
- Saint Luke's Cancer Institute · Kansas City, Missouri
- Duke University · Durham, North Carolina
- Huntsman Cancer Institute · Salt Lake City, Utah
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify